In patients with heart failure and preserved ejection fraction (HFpEF), the EMPEROR-PRESERVED trial demonstrated that empagliflozin significantly reduced cardiovascular mortality, heart failure-related hospitalizations, and decline in kidney function regardless of underlying diabetes status.